BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 25724706)

  • 41. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
    Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
    J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 44. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.
    Senore C; Zappa M; Campari C; Crotta S; Armaroli P; Arrigoni A; Cassoni P; Colla R; Fracchia M; Gili F; Grazzini G; Lolli R; Menozzi P; Orione L; Polizzi S; Rapi S; Riggi E; Rubeca T; Sassatelli R; Visioli C; Segnan N
    Gut; 2020 Mar; 69(3):523-530. PubMed ID: 31455608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
    Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?
    van Turenhout ST; Oort FA; van der Hulst RW; Visscher AP; Terhaar sive Droste JS; Scholten P; Bouman AA; Meijer GA; Mulder CJ; van Rossum LG; Coupé VM
    BMC Gastroenterol; 2014 Dec; 14():217. PubMed ID: 25528043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study.
    Shahidi N; Gentile L; Gondara L; Hamm J; McGahan CE; Enns R; Telford J
    Can J Gastroenterol Hepatol; 2016; 2016():4650471. PubMed ID: 28116286
    [No Abstract]   [Full Text] [Related]  

  • 48. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
    Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
    Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
    Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
    Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening.
    Salas D; Vanaclocha M; Ibáñez J; Molina-Barceló A; Hernández V; Cubiella J; Zubizarreta R; Andreu M; Hernández C; Pérez-Riquelme F; Cruzado J; Carballo F; Bujanda L; Sarasqueta C; Portillo I; de la Vega-Prieto M; Morillas JD; Valentín V; Lanas A; Quintero E; Castells A
    Cancer Causes Control; 2014 Aug; 25(8):985-97. PubMed ID: 24859111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fecal hemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia.
    Kim NH; Kwon MJ; Kim HY; Lee T; Jeong SH; Park DI; Choi K; Jung YS
    Dig Liver Dis; 2016 Jun; 48(6):667-72. PubMed ID: 27012445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis.
    Selby K; Levine EH; Doan C; Gies A; Brenner H; Quesenberry C; Lee JK; Corley DA
    Gastroenterology; 2019 Dec; 157(6):1494-1505. PubMed ID: 31472152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct comparison of ten quantitative fecal immunochemical tests for hemoglobin stability in colorectal cancer screening.
    Gies A; Cuk K; Schrotz-King P; Brenner H
    Clin Transl Gastroenterol; 2018 Jul; 9(7):168. PubMed ID: 29976921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Timing and Risk Factors for a Positive Fecal Immunochemical Test in Subsequent Screening for Colorectal Neoplasms.
    Chiang TH; Lee YC; Liao WC; Chung JH; Chiu HM; Tu CH; Chen SC; Wu MS
    PLoS One; 2015; 10(9):e0136890. PubMed ID: 26332318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
    Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
    Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer.
    Baldacchini F; Bucchi L; Giuliani O; Mancini S; Ravaioli A; Vattiato R; Giorgi Rossi P; Campari C; Canuti D; Di Felice E; Mezzetti F; Sassoli de Bianchi P; Ferretti S; Falcini F;
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2361-2369. PubMed ID: 32827723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fecal immunochemical testing results and characteristics of colonic lesions.
    van Doorn SC; Stegeman I; Stroobants AK; Mundt MW; de Wijkerslooth TR; Fockens P; Kuipers EJ; Bossuyt PM; Dekker E
    Endoscopy; 2015 Nov; 47(11):1011-7. PubMed ID: 26126163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.